If you or someone you know has multiple myeloma, I HIGHLY recommend world renowned medical oncologist and multiple myeloma expert Dr. Landgren.
C. Ola Landgren, M.D., Ph.D
Posted in biotech/medical
Category: biotech/medical – Page 1,203
Strange libraries of supplementary genes nicknamed “Borg” DNA appear to supercharge the microbes that possess them, giving them an uncanny ability to metabolize materials in their environment faster than their competitors.
By learning more about the way organisms use these unusual extrachromosomal packets of information, researchers are hoping to find new ways of engineering life to take a big bite out of methane emissions.
In the wake of a study publicized last year (and now published in Nature), researchers have continued to analyze the diversity of sequences methane-munching microbes store in these unusual genetic depositaries in an effort to learn more about the evolution of life.
A drug has been identified by researchers at Tokyo Medical and Dental University (TMDU) that replicates the benefits of exercise on mice’s bones and muscles.
You can look and feel better by keeping up a regular exercise schedule, but did you know that exercise also supports bone and muscle health? Locomotor fragility, which affects people who are unable to exercise, causes the muscles and bones to deteriorate. Recently, Japanese researchers discovered a new drug that, by producing effects comparable to those of exercise, may help treat locomotor frailty.
Physical inactivity can result in a weakening of the muscles (known as sarcopenia) and bones (known as osteoporosis). Exercise dispels this frailty by boosting muscular strength and suppressing bone resorption while simultaneously promoting bone formation. Exercise therapy, however, cannot be used in every clinical situation. When patients have dementia, cerebrovascular disease, or are already bedridden, drug therapy may be very helpful for treating sarcopenia and osteoporosis. However, there is no one drug that targets both tissues at the same time.
A new discovery could be a game-changer for patients with type 2 diabetes. Researchers at the Diabetes, Obesity, and Metabolism Institute (DOMI) at the Icahn School of Medicine at Mount Sinai have discovered a therapeutic target for the preservation and regeneration of beta cells (β cells), the cells in the pancreas that produce and distribute insulin. The finding could also help millions of individuals throughout the globe by preventing insulin resistance. The study was recently published in the journal Nature Communications.
Nature Communications is a peer-reviewed, open access, multidisciplinary, scientific journal published by Nature Research. It covers the natural sciences, including physics, biology, chemistry, medicine, and earth sciences. It began publishing in 2010 and has editorial offices in London, Berlin, New York City, and Shanghai.
Most scientists believe that the structure of the adult brain is generally rigid and incapable of rapid changes. However, new research has now revealed that this is not true. In a new study, German scientists have shown that in-patient treatment for depression can lead to an increase in brain connectivity. Moreover, those individuals who respond well to this treatment show a greater increase in connectivity than those who don’t.
Presenting the work at the European College for Neuropsychopharmacology Congress in Vienna, lead researcher, Professor Jonathan Repple said:
“This means that the brain structure of patients with serious clinical depression is not as fixed as we thought, and we can improve brain structure within a short time frame, around 6 weeks. We found that if this treatment leads to an increase in brain connectivity, it is also effective in tackling depression symptoms. This gives hope to patients who believe nothing can change and they have to live with a disease forever, because it is “set in stone” in their brain.”
The discovery that earned Japan’s Shinya Yamanaka the 2012 Nobel Prize in Medicine has paved the way for new research proving that aging is a reversible process. Currently just being tested on lab mice, will the cellular reprogramming soon offer eternal youth?
A newly identified colon cancer gene may drive the disease by making the environment in the vicinity of tumors more hospitable to them, researchers say. The…
Preclinical and clinical evidence for exercise as a senescence-targeting therapy and areas needing further investigation are discussed.
Will humans be able to grow replacement organs? LyGenesis aims to prove it can be done.
LyGenesis is a biomedical company hoping to deliver a technology that will allow patients to grow functioning organs. If successful the company’s cell therapies will disrupt organ transplantation allowing patients to grow their own. Instead of surgery, a person will do what some amphibians and reptiles do today when they lose a limb or tail.
The company is using the inherent nature of lymph nodes and their evolutionary function, turning them into rapid bioreactors. Our lymph nodes already do this when they produce infection-fighting T-cells. But LyGenesis’ therapies turn donated organ cells into biofactories that can become a source for producing viable organs in multiple patients. The only minimally invasive procedure involved is the engrafting of the cells into a patient’s lymph nodes to begin the process of organ development.
Dr_Microbe/iStock.
Called Upstaza, the therapy not only improved the symptoms of all participants in the small-scale trial but also gave some children the ability to walk and talk for the first time.